絞り込み

16737

広告

「こころを読む」能力を初めてサルから特定 自閉症治療法確立に貢献 新潟大など (財経新聞)

厚生労働省によると自閉症の症状をもつ人の割合は、約100人に1人いるといわれている。だが自閉症の背後にある脳のメカニズムについて謎が多いという。新潟大学は1日、...

  1. [企業] CAR-Tを開発するGilea...
  2. 「医療機関向け情報(治療ガイドライン、臨...
  3. チタンを用いた生体軟組織用の強力瞬間接着...
  4. [企業] AstraZenecaからRe...

ニュース一覧

VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.

著者 El Weshi A , Memon M , Raja M , Bazarbashi S , Rahal M , El Foudeh M , Pai C , Allam A , El Hassan I , Ezzat A
Am J Clin Oncol.2004 Oct ; 27(5):529-34.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. aweshi@healthgulf.com

スターを付ける スターを付ける     (123view , 0users)

Full Text Sources

Medical

Miscellaneous

Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease. There is no standard salvage chemotherapy regimen available in this context. In this study the authors reviewed their experience with the combination of etoposide, ifosfamide, and cisplatin in adult patients with recurrent or refractory disease. From February 1997 through December 2001, they evaluated the efficacy of etoposide (75 mg/m2/day for 5 days), ifosfamide (1,200 mg/m2/day for 5 days), and cisplatin (20 mg/m2/day for 5 days) combination chemotherapy (VIP regimen), as second-line salvage therapy in 27 patients with recurrent or refractory ET. All patients were evaluated for response, time to progression, and overall survival. Twenty-one male and 6 female patients with recurrent (n = 14) and refractory (n = 13) disease were treated with the VIP regimen. Median age was 18 years (range, 16-34 years). Twenty-two patients were previously treated with vincristine, Adriamycin, ifosfamide, and actinomycin-D; and 5 patients were treated with cyclophosphamide, Adriamycin, and vincristine. Sites of recurrent or progressive disease included local (n = 3), distant (n = 11), and both local and distant (n = 13). A total of 129 cycles of VIP were given (median, 5 cycles/patient; range, 1-14 cycles/patient). One patient (4%) had a complete response (CR) and 8 patients (30%) had a partial response (PR), for an overall response rate of 34%. The median number of cycles given to patients with CR + PR was 6 (range, 3-14 cycles). Nine patients (33%) had stable disease and 9 (33%) had disease progression. Median time to progression and median overall survival were 6.6 months and 8.1 months respectively for all patients, and 12.8 months and 14.2 months respectively for responders. There were no toxic deaths. Major toxicities included grade IV granulocytopenia in 19 patients and grades III/IV thrombocytopenia in 15 patients. At a median follow-up of 8 months (range, 2-56 months), 24 patients died of disease progression, 2 patients are alive with disease, and 1 patient is alive with no evidence of disease. The authors conclude that the VIP combination is active in patients with recurrent/refractory ET, with acceptable toxicity, and offers good palliation. Cisplatin-based combination chemotherapy merits further investigation, possibly as first-line treatment in this disease.
PMID: 15596925 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード